Favrot M C, Michon J, Floret D, Cochat C, Negrier S, Mathiot C, Coze C, Zucker J M, Franks C R, Bouffet E
Centre Léon Bérard, Lyon, France.
Pediatr Hematol Oncol. 1990;7(3):275-84. doi: 10.3109/08880019009033403.
Four children with persistent neuroblastoma after marrow ablative chemoradiotherapy and autologous bone marrow transplantation received continuous infusion of recombinant interleukin 2, 75 to 120 days after the graft. Recombinant interleukin 2 therapy did not induce any major or nonreversible toxicity, hematological toxicity in particular. One patient entered complete remission for 9 months and a second patient had a long-lasting normalization of urinary catecholamine metabolites with more than 50% regression of bone marrow metastases (8 months). In three children, recombinant interleukin 2 and a second patient entered complete remission for 9 months therapy was followed by major increase and activation of circulating natural killer cells which amounted to 80% of the circulating mononuclear cells.
4名在接受骨髓清除性放化疗和自体骨髓移植后仍患有持续性神经母细胞瘤的儿童，在移植后75至120天接受了重组白细胞介素2的持续输注。重组白细胞介素2治疗未引起任何严重或不可逆的毒性，尤其是血液学毒性。1例患者完全缓解9个月，另1例患者尿儿茶酚胺代谢产物长期正常化，骨髓转移灶消退超过50%（8个月）。在3名儿童中，重组白细胞介素2治疗后循环自然杀伤细胞显著增加并被激活，其数量占循环单核细胞的80%，另有1例患者完全缓解9个月。
